Cormorant Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-200,000
| Closed | -$11.9M | – | 53 |
|
|
2017
Q3 | $11.9M | Hold |
200,000
| – | – | 2.11% | 15 |
|
|
2017
Q2 | $15.8M | Hold |
200,000
| – | – | 2.62% | 15 |
|
|
2017
Q1 | $16.6M | Sell |
200,000
-210,000
| -51% | -$17.4M | 2.41% | 14 |
|
|
2016
Q4 | $32.5M | Sell |
410,000
-45,995
| -10% | -$3.65M | 4.38% | 5 |
|
|
2016
Q3 | $31.9M | Sell |
455,995
-50,000
| -10% | -$3.5M | 3.52% | 7 |
|
|
2016
Q2 | $19.6M | Buy |
505,995
+5,995
| +1% | +$233K | 2.78% | 9 |
|
|
2016
Q1 | $20.3M | Buy |
500,000
+100,000
| +25% | +$4.05M | 3.05% | 9 |
|
|
2015
Q4 | $35.5M | Buy |
400,000
+100,000
| +33% | +$8.87M | 4.24% | 4 |
|
|
2015
Q3 | $22.2M | Hold |
300,000
| – | – | 3.55% | 7 |
|
|
2015
Q2 | $24.3M | Sell |
300,000
-416,500
| -58% | -$33.7M | 3.23% | 8 |
|
|
2015
Q1 | $30M | Buy |
716,500
+316,500
| +79% | +$13.3M | 4.64% | 4 |
|
|
2014
Q4 | $6.2M | Hold |
400,000
| – | – | 0.96% | 32 |
|
|
2014
Q3 | $5.06M | Hold |
400,000
| – | – | 1.04% | 29 |
|
|
2014
Q2 | $5.73M | Hold |
400,000
| – | – | 1.52% | 25 |
|
|
2014
Q1 | $5.1M | Buy |
+400,000
| New | +$5.1M | 1.17% | 31 |
|